Whole Body Health Sale

Life Extension Magazine

Life Extension Magazine October 2009
Reports

Bioidentical Hormones:
Why Are They Still Controversial?

White Paper Authored by the Life Extension Foundation® www.lef.org

Conclusion

Dr. Kent Holtorf, MD, a specialist in bioidentical hormone therapy and anti-aging medicine stated:

“A thorough review of the medical literature clearly supports the claim that bioidentical hormones have some distinctly different, often opposite, physiological effects to those of their synthetic [non-bioidentical counterpart] hormones. With respect to the risk for breast cancer, heart disease, heart attack, and stroke, substantial scientific and medical evidence demonstrates that bioidentical hormones are safer and more efficacious forms of HRT than commonly used synthetic versions.”82

Medroxyprogesterone acetate
Click Here For Larger Image

Given the preponderance of evidence, maturing women should feel confident that bioidentical hormone replacement, when appropriately prescribed, offers a safer and potentially even more effective alternative to conventional hormone replacement with non-bioidentical hormone drugs to help relieve menopausal symptoms and optimize long-term health. The addition of several proven nutrients to a bioidentical hormone regimen may help optimize estrogen metabolism and reduce cancer risk even further, offering an optimal, balanced approach to health maintenance.

If you have any questions on the scientific content of this article, please call a Life Extension® Health Advisor at 1-866-864-3027 or visit www.lef.org.

Acknowledgement: The Life Extension Foundation® would like to thank the following diverse group of experts in the scientific disciplines of allopathic medicine, nutrition, biochemistry, and integrative health care for their independent, peer-review of this position paper.

John Boik, PhD

James Cennamo, DO

Mark L. Gordon, MD

Steven Harris, MD

Kent Holtorf, MD

Richard Kratz, MD

Peter Langsjoen, MD

Erika Schwartz, MD

Jonathan Wright, MD

References

1. JAMA. 2002 Jul 17;288(3):321-33.

2. JAMA. 2004 Apr 14;291(14):1701-12.

3. Ann Intern Med. 2004 Jul 20;141(2):118-25.

4. https://www.health.harvard.edu/newsweek/

What-are-bioidentical-hormones.htm.

5. Climacteric. 2002 Sep;5(3):229-35.

6. J Steroid Biochem Mol Biol. 2005 Jul;96(2):95-108.

7. Breast Cancer Res Treat. 2001 Aug;68(3):187-98.

8. J Clin Endocrinol Metab. 1999 Dec;84(12):4559-65.

9. Cancer Res. 1992 Dec 1;52(23):6539-46.

10. Mol Cell Endocrinol. 1994 Jun;102(1-2):45-52.

11. Cancer Res. 1990 Dec 15;50(24):7858-62.

12. Biochem Biophys Res Commun. 1987 Jun 15;145(2):706-11.

13. Br J Cancer. 1993 May;67(5):945-52.

14. Breast Cancer Res Treat. 2007 Jan;101(2):125-34.

15. Breast Cancer Res Treat. 1998 Apr;48(3):221-9.

16. Am J Obstet Gynecol. 1996 Jan;174(1 Pt 1):93-100.

17. Cancer Lett. 1986 Feb;30(2):213-8.

18. Fertil Steril. 1995 Apr;63(4):785-91.

19. Fertil Steril. 1998 May;69(5):963-9.

20. Climacteric. 2003 Sep;6(3):221-7.

21. Jpn J Cancer Res. 1985 Aug;76(8):699-704.

22. J Gynecol Obstet Biol Reprod (Paris). 1990;19(3):269-74.

23. J Steroid Biochem Mol Biol. 2000 Jun;73(3-4):171-81.

24. Breast Cancer Res Treat. 1986;8(3):179-88.

25. Int J Cancer. 2005;114:448–54.

26. JAMA. 2003 Jun 25;289(24):3243-53.

27. Cancer Causes Control. 2002 Nov;13(9):847-54.

28. Br J Cancer. 2005 Jun 6;92(11):2049-58.

29. Br J Cancer. 2005 Apr 11;92(7):1293-7.

30. Cancer Epidemiol Biomarkers Prev. 2002 Jul;11(7):593-600.

31. Int J Cancer. 2004 May 1;109(5):721-7.

32. Maturitas. 2004 Sep 24;49(1):44-50.

33. Int J Cancer. 1999 May 5;81(3):339-44.

34. JAMA. 2000 Aug 9;284(6):691-4.

35. J Natl Cancer Inst. 2000 Feb 16;92(4):328-32.

36. Am J Obstet Gynecol. 2004 Apr;190(4):1141-67.

37. Obstet Gynecol. 2002 Dec;100(6):1148-58.

38. JAMA. 2003 Jun 25;289(24):3254-63.

39. Lancet. 2003 Aug 9;362(9382):419-27.

40. Cancer Causes Control. 2002 Aug;13(6):583-90.

41. Lancet. 1997 Oct 11;350(9084):1047-59.

42. JAMA. 2000 Jan 26;283(4):485-91.

43. Am J Epidemiol. 1998;147:S45.

44. Cancer Causes Control. 1999 Aug;10(4):253-60.

45. JAMA. 2002 Feb 13;287(6):734-41.

46. Steroids. 2000 Oct;65(10-11):659-64.

47. J Clin Endocrinol Metab. 2001 Jan;86(1):16-23.

48. Acta Obstet Gynecol Scand. 2003 Jul;82(7):335-44.

49. Breast Cancer Res Treat. 2008 Jan;107(1):103-11.

50. Cancer Detect Prev. 1999;23(4):290-6.

51. Int J Cancer. 2004 Nov 1;112(2):312-8.

52. Am J Epidemiol. 1981 Aug;114(2):209-17.

53. Cancer Epidemiol Biomarkers Prev. 2002 Apr;11(4):361-8.

54. Eur J Cancer. 1994;30A(4):445-8.

55. Br J Cancer. 1996 Jun;73(12):1552-5.

56. Yakushigaku Zasshi. 2001;36(1):70-5.

57. Fertil Steril. 1999 Sep;72(3):389-97.

58. Exp Clin Psychopharmacol. 2007 Oct;15(5):427-44.

59. Climacteric. 2008 Aug;11(4):273-9.

60. www.karger.com/gazette/66/mcewen/art_05.htm.

61. Endocrinology. 2004 Dec;145(12):5745-56.

62. Fertil Steril. 2000 Mar;73(3):516-21.

63. Hum Reprod Update. 1999 Jul-Aug;5(4):365-72.

64. Best Pract Res Clin Obstet Gynaecol. 2008 Apr;22(2):391-405.

65. Menopause. 2005 Mar;12(2):232-7.

66. Mol Endocrinol. 1997 Nov;11(12):1868-78.

67. Cancer. 1989 May 1;63(9):1685-92.

68. Cancer Res. 2004 Jan 1;64(1):423-8.

69. Science. 1997 Sep 5;277(5331):1508-10.

70. Proc Natl Acad Sci USA. 1996 Jun 11;93(12):5925-30.

71. J Steroid Biochem. 1986 Jan;24(1):77-83.

72. Recent Prog Horm Res. 2000;55:163-93.

73. Physiol Rev. 2001 Oct;81(4):1535-65.

74. Oncogene. 2005 Oct 6;24(44):6605-16.

75. Endocr Relat Cancer. 2004 Sep;11(3):537-51.

76. Breast. 2002 Aug;11(4):295-300.

77. Chem Biol. 2001 May;8(5):427-36.

78. Oncogene. 2000 Oct 12;19(43):4970-8.

79. Proc Natl Acad Sci USA. 2000 Jan 4;97(1):337-42.

80. Endocrinology. 2006 Sep;147(9):4132-50.

81. Proc Natl Acad Sci USA. 2002 Jun 25;99(13):8562-7.

82. Postgrad Med. 2009 Jan;121(1):73-85.

83. Int J Cancer. 2004 Oct 20;112(1):130-4.

84. Sitieri PK, Sholtz PI, Cirillo PM, et al. Prospective study of estrogens during pregnancy and the risk of breast cancer. Unpublished study performed in at the Public Health Institute in Oakland, California, and funded by the US Army Medical Research and Material Command under DAMD 17- 99-1-9358.

85. N Engl J Med. 1975 Dec 4;293(23):1167-70.

86. Am J Obstet Gynecol. 1977 Mar 15;127(6):572-80.

87. Am J Epidemiol. 2009 Jul 1;170(1):12-23.

88. Lancet. 1999 May 29;353(9167):1824-8.

89. Eur J Obstet Gynecol Reprod Biol. 1995 Sep;62(1):101-6.

90. Fertil Steril. 2003 Jan;79(1):221-2.

91. Menopause. 2003 Jul;10(4):373-4.

92. Menopause. 2003 Jul-Aug;10(4):374-7.

93. Maturitas. 2005 Oct 16;52(2):111-8.

94. J Am Coll Cardiol. 2003 Apr 16;41(8):1358-63.

95. Arterioscler Thromb Vasc Biol. 2004 Oct;24(10):e164-7.

96. Climacteric. 2003 Mar;6(1):45-52.

97. MedGenMed. 2006;8(3):40.

98. Climacteric. 2004 Dec;7(4):347-56.

99. Fertil Steril. 1993 May;59(5):992-7.

100. Maturitas. 1994 Aug;19(2):103-15.

101. J Steroid Biochem Mol Biol. 2007 Mar;103(3-5):708-11.

102. Cancer Res. 2005 Jun 15;65(12):5470-9.

103. Am J Public Health. 2006 Feb;96(2):252-61.

104. J Nutr. 2004 May;134(5):1134-8.

105. Nutr Cancer. 2002;42(1):1-9.

106. Cancer Res. 1999 Aug 15;59(16):3991-7.

107. Cancer Epidemiol Biomarkers Prev. 2000 May;9(5):477-85.

108. Mutat Res. 2007 May;635(2-3):90-104.

109. Cancer Res. 2005 Sep 15;65(18):8548-57.

110. Cancer Epidemiol Biomarkers Prev. 2000 Aug;9(8):773-9.

111. J Natl Cancer Inst. 1997 May 21;89(10):718-23.

112. J Cell Biochem.Suppl. 1997;28-29:111-6.

113. Cancer Epidemiol Biomarkers Prev. 2007 Mar;16(3):538-45.

114. Am J Clin Nutr. 1999 Sep;70(3 Suppl):439S-50S.

115. J Natl Cancer Inst. 2003 Jun 18;95(12):906-13.

116. Cancer Epidemiol Biomarkers Prev. 2003 Jul;12(7):665-8.

117. Lancet. 1991 May 18;337(8751):1197-200.

118. Cancer Lett. 1990 Jan;49(1):51-7.

119. Isr J Med Sci. 1995 Feb;31(2-3):101-5.

120. Carcinogenesis. 1986 Sep;7(9):1463-6.

121. Anticancer Res. 1995 May;15(3):805-10.

122. Int J Cancer. 2004 Sep 1;111(3):440-3.

123. Eur J Cancer. 2004 Jan;40(1):84-9.

124. Br J Cancer. 2007 Apr 10;96(7):1139-46.

125. Cancer Epidemiol Biomarkers Prev. 2007 Jul;16(7):1443-8.

126. Simone CB. Cancer and Nutrition. Lawrenceville, NJ: Princeton Institute; 2005.

127. Am J Clin Nutr. 2007 Jun;85(6):1586-91.

128. Nutr Rev. 2008 Oct;66(10 Suppl 2):S116-24.

129. N Engl J Med. 2000 Nov 23;343(21):1566-8.

130. Recent Results Cancer Res. 2003;164:99-110.

131. J Am Coll Cardiol. 2000 Dec;36(7):2154-9.

132. Circulation. 2007 Feb 20;115(7):840-5.

133. Arterioscler Thromb Vasc Biol. 1998 Jul;18(7):1164-71.

134. Circulation. 1996 Nov 1;94(9):2221-7.

135. Arterioscler Thromb Vasc Biol. 1997 Jan;17(1):217-21.

136. Endocrinology. 1997 Aug;138(8):3330-9.

137. Cardiovasc Pathol. 2000 Nov;9(6):317-22.

138. Arteriosclerosis. 1990 Nov;10(6):1051-7.

139. J Intern Med. 2008;263(3):256-73.

140. Maturitas. 1990 Jun;12(2):89-97.

141. JAMA. 1995 Jan 18;273(3):199-208.

142. Eur J Clin Invest. 1983 Dec;13(6):447-53.

143. Fertil Steril. 1981 Feb;35(2):172-9.

144. Clin Pharmacol Ther. 1980 Nov;28(5):602-4.

145. N Engl J Med. 1981 Mar 5;304(10):560-3.

146. Acta Obstet Gynecol Scand Suppl. 1984;127:1-37.

147. Am J Obstet Gynecol. 1985 Mar 15;151(6):746-50.

148. Am J Obstet Gynecol. 1987 Jan;156(1):66-71.

149. Hum Reprod. 2000 May;15(5):1028-36.

150. Nippon Ronen Igakkai Zasshi. 1996 May;33(5):353-9.

151. Life Sci. 2002 May 24;71(1):31-42.

152. J Womens Health Gend Based Med. 2000 May;9(4):381-7.

153. Menopause. 2002 Jul;9(4):253-63.

154. Obstet Gynecol. 1989 Apr;73(4):606-12.

155. Obstet Gynecol. 2002 Nov;100(5 Pt 1):853-63.

156. Menopause. 2001 Jan;8(1):10-6.

157. Clin Ther. 2001 Jul;23(7):1099-115.

158. JAMA. 1978 Apr 21;239(16):1638-41.

159. Horm Metab Res. 1987 Nov;19(11):579-84.

160. J Obstet Gynaecol Res. 1996 Jun;22(3):259-65.

161. Nippon Sanka Fujinka Gakkai Zasshi. 1996 Feb;48(2):83-8.

162. J Bone Miner Metab. 1998; 16:21-6.

163. Menopause. 2004 Jan;11(1):49-56.

164. N Engl J Med. 1993 Sep 9;329(11):753-6.

165. Eur J Obstet Gynecol Reprod Biol. 1993 Sep;51(1):29-33.

166. Orv Hetil. 1995 Feb 12;136(7):343-5.

167. Maturitas. 2001 Sep 28;39(3):253-7.

168. J Cosmet Dermatol. 2006 Mar;5(1):3-8.

169. Menopause Int. 2007 Jun;13(2):60-4.

170. Clin Interv Aging. 2007;2(3):283-97.

171. Exp Dermatol. 2002 Dec;11(6):487-502.

172. Eur J Obstet Gynecol Reprod Biol. 2007 Feb;130(2):202-5.

173. Int J Dermatol. 1996 Sep;35(9):669-74.

174. Br Med J (Clin Res Ed). 1983 Nov 5;287(6402):1337-8.

175. Arch Dermatol. 1997 Mar;133(3):339-42.

176. Altern Med Rev. 1998 Apr;3(2):101-13.

177. Maturitas. 1994 Nov;20(1):25-30.

178. Climacteric. 2007 Aug;10(4):289-97.

179. Essex Testing Clinic, Inc. Data on file.

180. Endocr Metab Immune Disord Drug Targets. 2009 Mar;9(1):29-37.

181. J Sex Med. 2008 Oct;5(10):2282-90.

182. Gynecol Endocrinol. 2009 Jan;25(1):12-20.

183. Rev Med Suisse. 2007 Mar 28;3(104):792-6.

184. N Engl J Med. 2008 Nov 6;359(19):2005-17.

185. Am J Clin Nutr. 2009 May;89(5):1459-67.

186. Metabolism. 2008 Jun;57(6):838-44.

187. J Clin Endocrinol Metab. 1990 Feb;70(2):473-9.

188. Obes Rev. 2004 Nov;5(4):197-216.

189. Maturitas. 2008 May 20;60(1):10-8.

190. Am J Obstet Gynecol. 1998 Jan;178(1 Pt 1):101-7.

191. Acta Diabetol. 2003 Oct;40 Suppl 1:S191-5.

192. Eur J Contracept Reprod Health Care. 2000 Dec;5 Suppl 3:9-16.

193. Cancer Lett. 1997 Mar 19;114(1-2):169-70.

194. J Endocrinol. 1996 Sep;150 SupplS259-65.

195. Cell Cycle. 2008 Apr 1;7(7):917-24.

196. Cancer Prev Res (Phila Pa). 2009 Jun;2(6):598-604.

197. Mol Cancer Ther. 2007 Apr;6(4):1433-9.

198. Cancer Res. 2007 Dec 15;67(24):11840-7.

199. Carcinogenesis. 2008 Jan;29(1):93-9.

200. Am J Clin Nutr. 2008 Jun;87(6):1952-8.

201. Am J Clin Nutr. 2009 Apr;89(4):1132-7.

202. Nutr Cancer. 2004;50(2):161-7.

203. Lancet. 2005 Oct 29;366(9496):1558-60.

204. Epidemiology. 2000 Nov;11(6):635-40.

205. Otolaryngol Head Neck Surg. 2001 Mar;124(3):241-7.

206. Cancer Epidemiol Biomarkers Prev. 1997 Jul;6(7):505-9.

207. Epidemiology. 2006 Jan;17(1):80-8.

208. Steroids. 2003 Jan;68(1):65-72.

209. Cancer Res. 1999 Mar 15;59(6):1244-51.

210. Cancer Res. 1994 Nov 15;54(22):5848-55.

211. Jpn J Cancer Res. 1995 Feb;86(2):146-54.

212. Cancer Causes Control. 1998 Dec;9(6):553-7.

213. JAMA. 2005 Sep 28;294(12):1493-504.

214. Am J Epidemiol. 2007 Oct 15;166(8):924-31.

215. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2005 Apr;27(2):258-61.

216. J Nutr. 2002 Feb;132(2):276-82.

217. Nutr J. 2005;430.

218. J Nutr. 1995 Mar;125(3 Suppl):777S-83S.

219. J Am Coll Nutr. 2001 Oct;20(5 Suppl):354S-62S.

220. J Natl Cancer Inst. 2003 Aug 6;95(15):1158-64.

221. Cancer Epidemiol Biomarkers Prev. 2005 Jan;14(1):81-90.

222. Asia Pac J Clin Nutr. 2006;15(1):21-9.

223. Int J Cancer. 2007 Jul 15;121(2):377-85.

224. Int J Cancer. 2002 Mar 1;98(1):78-83.

225. www.garfield.library.upenn.edu/histcomp/kritchevsky-d_auth-citing/node/7082.html

226. Biochem Med Metab Biol. 1990 Apr;43(2):83-92.

227. Cancer Detect Prev. 1997;21(2):178-90.

228. Altern Med Rev. 2002 Aug;7(4):336-9.

229. Slaga TJ, Quilici-Timmcke J. D-Glucarate: A Nutrient Against Cancer. Columbus, Ohio: McGraw-Hill; 1999.

230. Clin Cancer Res. 2005 May 15;11(10):3828-35.

231. Cancer Biol Ther. 2007 Dec;6(12):1938-43.

232. Cancer Lett. 2007 Jan 8;245(1-2):232-41.

233. Breast Cancer Res Treat. 2008 Feb;107(3):359-69.

234. J Exp Ther Oncol. 2002 Nov;2(6):350-9.

235. Cancer Detect Prev. 2007;31(6):499-504.

236. Ann NY Acad Sci. 2007 Jan;1095:428-40.

237. http://www.fasebj.org/cgi/content/meeting_abstract/22/1_MeetingAbstracts/1164.3.

238. Int J Cancer. 2003 Sep 10;106(4):574-9.